NCT ID NCT06034860

Title Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer

Types

 Phase
 Phase 1

 Date Added
 2023-09-13

Location California, United States

Indiana, United States Missouri, United States New York, United States Virginia, United States

Prior IO Allowed Yes
CRC-directed No

Status Active, not recruiting

Drugs MT-8421, Nivolumab, Opdivo

Tags MSI-H/ MMRd

NCT ID NCT06026774

Title Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System

Neoplasms

PhasePhase 1Date Added2023-09-07LocationChinaPrior IO AllowedYesCRC-directedYes

Status Recruiting

Drugs

Tags MSI-H/ MMRd, MSS/ MMRp

NCT ID NCT06014502

Title Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors

 Phase
 Phase 1

 Date Added
 2023-08-28

Location Arizona, United States

California, United States Louisiana, United States Texas, United States

Prior IO Allowed No CRC-directed No

StatusRecruitingDrugsIMGS-001TagsMSI-H/ MMRd

NCT ID NCT06013111

Title An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+

Locally Advanced and/or Metastatic Solid Tumors

PhasePhase 1Date Added2023-08-28LocationChinaPrior IO AllowedYesCRC-directedYesStatusRecruiting

Drugs

Tags MSI-H/ MMRd, MSS/ MMRp

NCT ID NCT06011772

Title A Phase 0 Study of EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF

Wild-Type Metastatic Colorectal Cancer

Phase Early Phase 1

Date Added 2023-08-25

Location New York, United States

Prior IO Allowed Yes
CRC-directed Yes

Status Active, not recruiting

Drugs fluorouracil, Irinotecan, Leucovorin, oxaliplatin

Tags MSI-H/ MMRd, MSS/ MMRp

NCT ID NCT06010901

Title A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib

Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.

PhasePhase 1Date Added2023-08-25LocationChinaPrior IO AllowedYesCRC-directedYes

Status Recruiting

Drugs Anlotinib hydrochloride capsules, Penpulimab Injection, TQB2618 injection

Tags MSI-H/ MMRd, MSS/ MMRp

NCT ID NCT06008119

Title Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Phase Phase 3

Date Added 2023-08-23

Location China

Prior IO Allowed Yes

CRC-directed Yes

Status Recruiting

Drugs Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab, Tunlametinib plus Vemurafenib

Tags MSI-H/ MMRd, MSS/ MMRp

NCT ID NCT06006923

Title Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

 Phase
 Phase 2

 Date Added
 2023-08-23

Location California, United States

Florida, United States Illinois, United States Michigan, United States Pennsylvania, United States Washington, United States

Prior IO Allowed No
CRC-directed Yes
Status Recruiting

Drugs Pembrolizumab, Regorafenib, Keytruda, Stivarga

Tags MSI-H/ MMRd

NCT ID NCT05999812

Title Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer

 Phase
 Phase 2

 Date Added
 2023-08-21

Location Texas, United States

Prior IO Allowed No CRC-directed Yes

Status Recruiting

Drugs all trans Retinoic Acid, Atezolizumab, Bevacizumab

Tags MSS/ MMRp

NCT ID NCT05990543

Title Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer

Phase 1, Phase 2

Date Added 2023-08-14

Location South Korea

Prior IO Allowed Yes
CRC-directed Yes

Status Active, not recruiting

Drugs Nelmastobart and Capecitabine

Tags MSI-H/ MMRd, MSS/ MMRp